
Ayan Mukherjee
Director of Biostatistics at Eli Lilly, specializing in Project Optimus and dose optimization in oncology clinical trials.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
Jul 21, 2026
Project Optimus and what you need to know about it
3:10
3:17
3:28
3:54
3:02
Maybe you can introduce us a little bit to what that is and where that was coming from.

Ayon MukherjeeGUEST
It's a very important topic, and it's been discussed worldwide in various different ways.

Ayon MukherjeeGUEST
So I will try to briefly summarize of what the overall background is and what the current trend is in terms of thought process on this topic.

Ayon MukherjeeGUEST
So traditionally, when cancers were treated with chemotherapies, the way the chemotherapy works is that it directly goes and burns the tumor cells, and that's why as the doses were increased, the toxicity used to increase due to the medication as well as the efficacy used to increase because more tumor cells were getting burnt.

Ayon MukherjeeGUEST
And therefore, mathematically, the assumption of efficacy and toxicity increasing monotonically with increase in dose was valid for traditional chemotherapy medication.
16 MINS LATER
19:55
What tools or documents that are available that make it easier for teams to introduce these kind of designs?
